TITLE

Statin Wars--Emphasis on Potency vs Event Reduction and Safety?

AUTHOR(S)
Lavie, Carl J.; Milani, Richard V.; O'Keefe, James H.
PUB. DATE
May 2007
SOURCE
Mayo Clinic Proceedings;May2007, Vol. 82 Issue 5, p539
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses various reports published within the issue, including one by W. Insull and colleagues about the effect of rosuvastatin on patients with low density lipoproteins (LDL)-C levels and another by M. C. Kontos and S. E. Joyner on the higher doses of statins combined with ezetimibe.
ACCESSION #
25242029

 

Related Articles

  • Goals of statin conversion program. Resch, Nina; Ito, Matthew K. // American Journal of Health-System Pharmacy;2/15/2002, Vol. 59 Issue 4, p380 

    Presents correspondence on the issue of statin conversion program. Criticisms over Ito and others' article about the goals of statin conversion program; Resch's study designed to measure the effect of a pharmacist-managed hyperlipidemia clinic on the attainment of low-density-lipoprotein (LDL)...

  • Try low-dose simvastatin in 'statin intolerance'.  // Pulse;5/26/2010, Vol. 70 Issue 18, p9 

    The article discusses a study conducted by Dutch researchers which found that low doses of simvastatin are tolerated by majority of statin-intolerant patients and reduce levels of low-density lipoprotein (LDL).

  • LDL: See how low you can go--without statins. ETINGIN, ORLI R. // Women's Health Advisor;Jun2012, Vol. 16 Issue 6, p1 

    The article focuses on the lowering of low-density lipoprotein (LDL) cholesterol without taking statin.

  • LDL--Lower is Better, But How Low Should We Go? Karpman, Harold L. // Internal Medicine Alert;10/29/2007, Vol. 29 Issue 20, p155 

    Statin therapy in patients with a very low LDL Cholesterol level (ie, less than 60 mg/dL) appears to be safe and is associated with improved survival.

  • Statins and Dyslipidemia: Should we be Looking Beyond LDL? Kuritzky, Louis // Internal Medicine Alert;5/15/2012, Vol. 34 Issue 9, p71 

    The article focuses on the use of statins, cardiovascular agents, in the treatment of dyslipidemia which lowers low-density lipoprotein cholesterol, a major agent in myocardial infarc­tion and stroke.

  • RUTHERFORD: PCSK9 inhibition improved LDL in patients with familial hypercholesterolemia. Costa, Samantha; Ellis, Brian; Foster, Melissa; Kalvaitis, Katie; Volansky, Rob // Endocrine Today;Dec2012, Vol. 10 Issue 12, p22 

    The article focuses on the results from the phase 2 RUTHERFORD trial which showed AMG 145 being responsible for low-density lipoprotein (LDL) reductions of up to 56% in combination with statin therapy with or without ezetimibe for patients with heterozygous familial hypercholesterolemia.

  • rosuvastatin safe, effective in adolescents.  // Infectious Diseases in Children;Apr2010, Vol. 23 Issue 4, p52 

    This article discusses a study on the safety and efficacy of rosuvastatin in reducing low density lipoprotein (LDL) levels.

  • Effectiveness of Combination Therapy With Statin and Another Lipid-Modifying Agent Compared With Intensified Statin Monotherapy. Tetsuro Tsujimoto; Ritsuko Yamamoto-Honda // Annals of Internal Medicine;11/4/2014, Vol. 161 Issue 9, p678 

    A letter to editor is presented in response to a article related to effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy in cardiovascular disorders by K. A. Gudzune and colleagues in 2014 issue of the periodical.

  • Rosuvastatin: A Viewpoint by Pang H. Chong. Chong, P.H. // Drugs;2002, Vol. 62 Issue 14, p2086 

    Presents views on hydroxymethylglytaryl coenzyme A reductase inhibitor rosuvastatin. Reduction of low-density lipoprotein-cholesterol levels; Dosage range; Frequency of creatinine kinase.

  • SANDS: Nearly identical regression in LDL, carotid IMT with statins alone, statins plus ezetimibe.  // Cardiology Today;Jan2009, Vol. 12 Issue 1, p12 

    The article presents findings of a study on the effect of low density lipoprotein (LDL) lowering with statins alone on patients with type 2 diabetes.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics